DXS reports significant advances in SMART Referrals and ExpertCare in FY24, eyes European expansion in FY25
() , a software company providing clinical decision support solutions, issued a brief operations and pipeline update ahead of its AGM meeting taking place on December 19, 2024.
DXS reported "good progress" in FY24 for both its Aios SMART Referrals and ExpertCare solutions, alongside an NHS price increase.
DXS' existing point of care solution was replaced with SMART Referrals, its new cloud-based system, and successfully integrated with the NHS Electronic Referral System during the period. DXS said SMART Referrals was now used for 10% of all referrals in England or an estimated 1.8 million per year. The product has been independently estimated to deliver c. £44m in net savings to the NHS.
DXS also reported that 22% of newly established Integrated Care Boards (ICBs) now had some of their practices using SMART Referrals. These practices cover c. 6.5m registered patients. Looking ahead, DXS aims to convert the remaining 6.5m GP practices to SMART Referrals, gaining further market share in the remaining ICBs.
Additionally, DXS updated on its ExpertCare product, a long-term condition therapeutic management solution. ExpertCare has now completed 75% of Phase 3 of a 4-phase Innovate UK grant through Health Innovate East, with DXS reporting positive results and York University conducting an economic impact assessment. The first commercial sale of ExpertCare was announced on October 29, 2024.
In terms of future expansion, DXS said it was targeting "at least one EU or other territory" to grow its footprint in FY25, with a further update expected in the coming months.
Follow News & Updates from DXS International:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.